List of Excipients in Branded Drug ACITRETIN

Company	Tradename	Ingredient	NDC	Excipient	Potential Generic Entry
Prasco Laboratories	ACITRETIN	acitretin	66993-894	CELLULOSE, MICROCRYSTALLINE
Prasco Laboratories	ACITRETIN	acitretin	66993-894	FERRIC OXIDE RED
Prasco Laboratories	ACITRETIN	acitretin	66993-894	FERRIC OXIDE YELLOW
Prasco Laboratories	ACITRETIN	acitretin	66993-894	FERROSOFERRIC OXIDE
Prasco Laboratories	ACITRETIN	acitretin	66993-894	GELATIN

Generic Drugs Containing ACITRETIN

Company	Ingredient	NDC	Excipient
Teva Pharmaceuticals USA Inc	acitretin	0093-1135	CELLULOSE, MICROCRYSTALLINE
Teva Pharmaceuticals USA Inc	acitretin	0093-1135	CROSPOVIDONE
Teva Pharmaceuticals USA Inc	acitretin	0093-1135	D&C YELLOW NO. 10
Teva Pharmaceuticals USA Inc	acitretin	0093-1135	D&C YELLOW NO. 10 ALUMINUM LAKE
Teva Pharmaceuticals USA Inc	acitretin	0093-1135	FD&C BLUE NO. 1

What are the Most Frequently-Used Excipients in ACITRETIN?

# Of NDCs	Excipient
1	AMMONIA
10	CELLULOSE, MICROCRYSTALLINE
1	CROSPOVIDONE
1	D&C YELLOW NO. 10
1	D&C YELLOW NO. 10 ALUMINUM LAKE

Acitretin Excipient Strategy and Commercial Opportunities

Last updated: August 26, 2026

Acitretin is a generic oral retinoid with limited conventional patent protection and a persistent formulation problem: poor aqueous solubility, high lipophilicity, and clinically important food-dependent absorption. The strongest commercial opportunities are differentiated oral formulations that improve exposure consistency, reduce dependence on high-fat meals, extend shelf life, or support adherence without altering the approved active ingredient.

The most credible product concepts are lipid-based capsules, self-emulsifying drug-delivery systems, smaller or easier-to-swallow capsules, and formulations with tighter impurity and oxidation control. A new excipient system would need to preserve acitretin stability, avoid interaction with the retinoid safety profile, and demonstrate bioequivalence or clinical superiority under FDA requirements.

What excipients are used in approved acitretin capsules?

Approved acitretin capsules generally use a conventional solid oral formulation with excipients such as lactose monohydrate, microcrystalline cellulose, sodium ascorbate, gelatin, titanium dioxide, and colorants. The precise composition varies by manufacturer and strength and must be confirmed against the current product label and FDA inactive-ingredient records.[1,2]

Formulation element	Typical role	Commercial relevance
Lactose monohydrate	Diluent	May limit use in patients with lactose intolerance; useful target for a lactose-free product
Microcrystalline cellulose	Filler and compression aid	Common, low-cost, and broadly accepted
Sodium ascorbate	Antioxidant	May help control oxidative degradation of a highly lipophilic retinoid
Gelatin	Capsule shell	Creates animal-origin and dietary restrictions; alternative vegetarian shells may differentiate the product
Titanium dioxide	Opacifier and colorant	Regulatory scrutiny varies by jurisdiction
Iron oxides or other colorants	Capsule identification	Can be replaced to support simplified excipient declarations
Printing inks	Product identification	Must remain compatible with capsule-shell storage and packaging

The current products are not dependent on an unusual proprietary excipient. That limits the defensive value of the incumbent formulation but creates room for reformulation, especially where the new composition addresses an identifiable performance limitation.

Why does acitretin need an excipient strategy?

Acitretin is practically insoluble in water and highly lipophilic. The FDA label states that absorption is enhanced when acitretin is taken with food, particularly a meal containing fat.[1] This creates an exposure-management problem because patients may take the drug under variable dietary conditions.

A formulation that reduces food dependence could offer the clearest commercial value. The development objective is not necessarily to maximize peak exposure. It is to produce predictable systemic exposure while maintaining a safety profile comparable to the reference product.

The main technical targets are:

1. Improve dissolution and dispersion in gastrointestinal fluid.
2. Reduce the difference between fed and fasted exposure.
3. Limit precipitation after dispersion of the lipid phase.
4. Control oxidation and retinoid-related degradation.
5. Preserve capsule integrity during long-term storage.
6. Avoid excipients that complicate labeling, tolerability, or global registration.

What formulation approaches are commercially attractive for acitretin?

Lipid-based and self-emulsifying systems

Lipid-based formulations are the most logical first development path. They can maintain acitretin in a solubilized state and promote dispersion after oral administration.

Candidate excipient classes include:

• Medium-chain triglycerides
• Long-chain triglycerides
• Mixed mono- and diglycerides
• Polyethylene glycol-based solubilizers
• Polysorbates
• Poloxamers
• Macrogol glycerides
• Phospholipids
• Nonionic surfactants

A self-emulsifying drug-delivery system, or SEDDS, could be filled into a hard capsule or softgel. A supersaturating SEDDS could add a precipitation inhibitor such as a polymeric excipient, although the choice would require compatibility and tolerability testing.

The central risk is that increased solubilization can also increase absorption. Because acitretin has serious teratogenicity warnings and exposure-related safety concerns, a formulation that materially increases systemic exposure could face a difficult regulatory and clinical path.

Solid dispersion

A solid dispersion can use a polymeric carrier to improve dissolution after capsule disintegration. Potential carriers include povidone, copovidone, hydroxypropyl cellulose, and hypromellose.

This approach may be more compatible with a conventional generic manufacturing platform than a liquid-filled softgel. It also permits a lactose-free or gelatin-free product architecture. The principal risks are recrystallization, moisture sensitivity, residual solvent control, and scale-up reproducibility.

Nanocrystal or amorphous formulations

Nanocrystals or amorphous solid dispersions could increase apparent dissolution rate. These systems may be technically effective but could be commercially excessive for a low-cost generic unless they produce a clinically meaningful reduction in food effect or a meaningful dose reduction.

A nanocrystal product would also create a more complex quality package involving particle-size distribution, solid-state characterization, dissolution discrimination, and process controls.

Cyclodextrin complexes

Cyclodextrins can improve apparent aqueous solubility, but their use in a chronic oral retinoid would require careful assessment of dose burden, gastrointestinal tolerability, cost, and manufacturability. Cyclodextrin inclusion is more attractive when the active ingredient can achieve a substantial solubility gain without an impractically large excipient load.

Alternative capsule shells

A hard capsule or softgel using hydroxypropyl methylcellulose could eliminate gelatin. This could support vegetarian, religious-dietary, or animal-origin positioning. The commercial benefit is likely incremental unless paired with a stronger value proposition, such as lactose-free composition, improved stability, or easier administration.

What excipient risks are specific to acitretin?

Acitretin presents a higher safety and regulatory burden than many generic dermatology products. The label contains a boxed warning for teratogenicity and strict pregnancy-prevention requirements.[1] Excipient selection therefore has to support, rather than complicate, risk management.

Alcohol-related considerations

Women of childbearing potential must avoid alcohol during acitretin treatment and for three years after stopping treatment because alcohol can promote conversion of acitretin to etretinate, a more lipophilic retinoid with prolonged persistence in the body.[1] Ethanol-containing excipients would be commercially unattractive and could create avoidable labeling and counseling complications.

The issue is not that every excipient containing an alcohol functional group is equivalent to ethanol. The practical development strategy is to avoid ethanol as an excipient and clearly characterize any solvent, residual solvent, or alcohol-containing processing material.

Oxidation and light sensitivity

Retinoids are vulnerable to oxidation and light-related degradation. Antioxidant selection, oxygen control, packaging, and capsule opacity should be assessed together. Sodium ascorbate is used in existing products, but alternative antioxidant systems could be evaluated if they improve impurity control or permit a lower excipient burden.

Capsule-shell migration and leakage

Liquid-filled formulations introduce risks of shell brittleness, plasticizer migration, leakage, fill-weight variation, and interaction between the fill and capsule shell. Softgel development would require long-term studies under ICH stability conditions, including moisture, oxygen, light, and temperature stress.

Excipient intolerance

A lactose-free product could address a defined patient subgroup. Surfactants and lipid excipients can produce gastrointestinal symptoms, and the label burden may increase as the excipient system becomes more complex. A commercial formulation should avoid solving dissolution while creating tolerability problems.

What formulation patents could protect an acitretin product?

A new acitretin formulation could be protected through composition, dosage form, manufacturing process, and method-of-use claims. The value of each claim category would depend on whether the formulation produces measurable clinical or pharmaceutical advantages.

Claim category	Potential subject matter	Relative value
Composition	Acitretin with defined lipid, surfactant, antioxidant, or polymer ratios	High if difficult to design around
Dosage form	Softgel, liquid-filled hard capsule, multiparticulate capsule	Moderate to high
Performance	Reduced fed/fasted variability or improved dissolution	High if supported by clinical data
Manufacturing	Controlled homogenization, encapsulation, drying, or solid-state process	Moderate
Stability	Defined impurity limits after accelerated storage	Moderate unless tied to a unique composition
Method of use	Administration independent of a high-fat meal or reduced dosing frequency	High only if clinically supported
Patient population	Patients unable to consume a high-fat meal or requiring a specific administration profile	Narrow but potentially useful

The strongest patent package would combine a composition claim with performance claims and a manufacturing claim. A broad claim covering “acitretin and a surfactant” would likely face substantial prior-art exposure. Narrower claims tied to defined excipient ratios, particle characteristics, dissolution profiles, or food-effect results would be more defensible.

When does acitretin lose exclusivity?

Acitretin has already lost primary U.S. market exclusivity. The branded product Soriatane was approved by FDA in 1996, and generic acitretin capsules are marketed in the United States.[1,3]

Exclusivity category	Acitretin status
New chemical entity exclusivity	Expired
Original product patent protection	Expired or no longer commercially controlling for standard acitretin capsules
Generic availability	Yes
Biosimilar exposure	None; acitretin is a small molecule
Orange Book importance	Relevant for any currently listed patents or regulatory exclusivity, but not a barrier to ordinary generic competition
Reformulation exclusivity	Possible only for a newly approved differentiated product meeting statutory requirements

A reformulated acitretin product could seek its own patents and potentially regulatory exclusivity if it meets the requirements for a new drug application or an eligible supplemental pathway. That protection would cover the improved formulation or approved use, not acitretin as a molecule generally.

What is the Orange Book status of acitretin?

The FDA Orange Book identifies approved drug products, reference-listed drugs, therapeutic equivalents, and applicable patent or exclusivity information.[3] Acitretin is marketed as a generic capsule product referencing the Soriatane product.

For a new acitretin formulation, the strategic question is whether the applicant can pursue an ANDA referencing the existing listed drug or must use an NDA pathway because of material differences in dosage form, formulation, route, or clinical performance. A lipid-based formulation with materially different excipients may require a more extensive regulatory package than a compositionally conventional capsule.

Patent certifications would depend on the Orange Book listings for the reference product and any listed patents relevant to the proposed product. A generic applicant could face Paragraph IV litigation only if it challenges an unexpired listed patent. For ordinary acitretin capsules, the commercial relevance of Paragraph IV risk is substantially lower than for a recently approved branded drug.

Are Paragraph IV challenges relevant to acitretin?

Paragraph IV litigation is not the primary barrier for standard acitretin generic entry because the product is already genericized. The more relevant litigation risk would arise from a newly patented reformulation.

A reformulated acitretin product could generate Paragraph IV exposure if:

• The new product is listed with formulation or use patents.
• An ANDA applicant seeks approval before those patents expire.
• The applicant certifies that the patents are invalid, unenforceable, or not infringed.
• The patent holder files suit within the statutory period.

The patent owner would need claims that cover the proposed generic product in a way that survives design-around strategies. Narrow excipient-ratio claims can be valuable but may be easier to avoid than claims tied to a clinically demonstrated performance profile.

Which companies are challenging acitretin exclusivity?

Generic acitretin is already commercially available from multiple manufacturers and distributors. The competitive field is therefore based on price, supply reliability, dosage-form availability, channel access, and formulation quality rather than a pending first generic event.

Publicly available FDA sources identify approved acitretin products and applicants, but manufacturer participation varies by strength, market availability, and time.[3] A live product-specific manufacturer ranking and current market-share analysis cannot be stated reliably without current commercial datasets.

The most plausible commercial entrants are:

• Conventional generic manufacturers seeking supply or portfolio expansion
• Dermatology-focused specialty pharmaceutical companies
• Contract development and manufacturing organizations with softgel capacity
• Reformulation companies targeting food-effect reduction
• Companies pursuing international products where capsule composition or dietary positioning has value

What FDA regulatory pathway applies to a new acitretin formulation?

Conventional generic capsule

A conventional capsule with the same active ingredient, strength, dosage form, route, and therapeutic equivalence objective would generally be evaluated through an ANDA pathway under section 505(j) of the Federal Food, Drug, and Cosmetic Act.[4]

The applicant would need to address:

• Pharmaceutical equivalence
• Bioequivalence
• Dissolution
• Impurity profile
• Stability
• Manufacturing controls
• Labeling
• Inactive-ingredient acceptability

Reformulated or clinically differentiated product

A formulation with a new dosage form, altered release profile, reduced food effect, or a clinically meaningful administration advantage may require an NDA or another regulatory strategy under section 505(b)(2).[4]

The development burden increases if the product claims:

• Bioavailability independent of food
• Improved tolerability
• Lower dose with equivalent efficacy
• Reduced dosing frequency
• A new patient population
• A new route or delivery system

For acitretin, a clinical advantage should be balanced against the risk that greater or more consistent exposure increases retinoid toxicity. The label already includes extensive warnings involving pregnancy, liver toxicity, lipid abnormalities, and skeletal effects.[1]

What commercial opportunities exist for acitretin excipients?

Reduced food-effect product

This is the highest-value opportunity. The existing label requires administration with food, and a product that provides more consistent exposure under ordinary meal conditions could improve usability. The opportunity is strongest if the formulation demonstrates:

• Lower fasted-to-fed pharmacokinetic variability
• Comparable total exposure to the reference product
• No clinically meaningful increase in peak concentration
• Comparable safety
• Clear patient instructions

Lactose-free product

A lactose-free capsule is a straightforward differentiation strategy. Its value is likely modest because lactose intolerance does not affect all acitretin users, but it can support pharmacy substitution resistance and specialty-channel positioning.

Vegetarian or non-gelatin capsule

A hydroxypropyl methylcellulose capsule could address dietary and animal-origin preferences. This is a secondary opportunity unless combined with a lipid-based or stability advantage.

Improved stability and packaging

A product with stronger impurity control, oxygen-barrier packaging, and improved thermal stability could reduce product loss and supply interruptions. This opportunity is operational rather than clinical, but it can matter in a small generic market where shortages or discontinuations create commercial openings.

Pediatric or low-dose flexibility

Acitretin is primarily used for severe psoriasis and other keratinization disorders. A lower-strength capsule, multiparticulate system, or accurately divisible dosage form could support dose titration. Pediatric positioning would require separate safety, dosing, and regulatory analysis because the product carries substantial systemic retinoid risks.

International formulation harmonization

A simplified excipient system can support filings in multiple jurisdictions. The main advantages are reduced country-specific inactive-ingredient issues, fewer colorant restrictions, and easier supply-chain management. Titanium dioxide, gelatin, lactose, and certain colorants can create jurisdiction-specific labeling or acceptability questions.

How strong is the patent estate for an acitretin reformulation?

The underlying molecule provides little exclusivity value. Patent strength would come from the formulation and evidence package.

Factor	Assessment
Molecule patent position	Weak for new-entry protection because acitretin is long established
Conventional capsule claims	Weak to moderate; substantial prior art and design-around risk
SEDDS or softgel claims	Moderate if supported by specific composition and performance data
Reduced food-effect claims	Potentially strong if clinically demonstrated
Manufacturing claims	Moderate; useful as a secondary barrier
Method-of-use claims	Variable and dependent on approved labeling
Litigation leverage	Higher for a differentiated NDA product than for an ordinary ANDA

A formulation patent should be drafted around measurable attributes, not only ingredient identity. Useful claim features can include excipient ratios, capsule fill composition, particle-size distribution, dissolution thresholds, precipitation behavior, and pharmacokinetic parameters.

What generic launch scenarios exist for acitretin?

Low-cost conventional generic

This strategy competes on price and supply. It requires limited formulation innovation and offers low protection from additional generic entrants.

Premium differentiated generic

A lactose-free, non-gelatin, or stability-optimized product can command limited premium pricing, particularly through specialty pharmacies or institutional contracts. The premium is unlikely to be durable without a clinically meaningful advantage.

Reformulated NDA product

A product that reduces food dependence or provides a clinically supported exposure advantage could support stronger pricing and patent protection. It would carry higher development costs, regulatory risk, and post-approval safety obligations.

Partnered specialty product

A formulation developer could license the product to a dermatology company with established prescriber relationships. The commercial rationale would depend on whether the partner can reach dermatologists and specialty pharmacies at lower cost than a standalone launch.

What licensing deals are relevant to acitretin?

Acitretin’s original branded product was associated with established pharmaceutical commercialization arrangements, while current generic supply is fragmented among approved applicants and distributors. A new excipient platform would more likely be licensed as a reformulation asset than as a molecule license.

Potential transaction structures include:

• Option-to-license after proof-of-concept pharmacokinetic data
• Regional rights for the United States, Europe, or emerging markets
• Co-development with a softgel manufacturer
• Supply-and-license arrangements with a dermatology company
• Royalty-bearing commercialization rights linked to patent issuance or approval

The strongest licensing package would include a completed formulation screen, comparative fed and fasted pharmacokinetics, stability data, a clear regulatory pathway, and composition-of-matter or formulation patent filings.

What revenue exposure does acitretin create?

Acitretin is a niche dermatology product rather than a large-volume primary-care medicine. Revenue exposure is concentrated in:

• Severe psoriasis
• Disorders of keratinization
• Dermatology specialty pharmacies
• Patients requiring long-term systemic retinoid management

The commercial ceiling is constrained by safety monitoring, teratogenicity restrictions, generic competition, and the availability of alternative psoriasis therapies, including biologics and newer oral agents.

The market can still support a differentiated product if it reduces practical treatment barriers. A formulation that removes the need for a high-fat meal may have greater commercial value than a cosmetic excipient change because it addresses a labeled administration requirement.

Key Takeaways

• Acitretin is a mature generic small molecule with no biosimilar risk and limited molecule-level exclusivity.
• The main formulation problem is poor solubility and food-dependent absorption.
• Lipid-based, self-emulsifying, solid-dispersion, and softgel systems are the leading technical options.
• The best commercial target is a formulation that reduces fed/fasted variability without increasing systemic exposure or toxicity.
• Lactose-free and non-gelatin products offer secondary differentiation.
• Ethanol should be avoided as an excipient because of acitretin’s conversion to etretinate in the presence of alcohol.
• Patent value would come from defined excipient compositions, performance parameters, manufacturing controls, and clinically supported food-effect claims.
• Standard generic competition is already established; commercial success depends on formulation differentiation, supply reliability, and specialty-channel execution.
• FDA pathway selection depends on whether the product is a conventional bioequivalent capsule or a clinically differentiated reformulation.
• A credible licensing package requires formulation, pharmacokinetic, stability, regulatory, and patent evidence.

FAQs

Can acitretin be formulated as a food-independent capsule?

Yes. A lipid-based or self-emulsifying formulation is the most plausible approach, but it must demonstrate comparable exposure and safety under fed and fasted conditions.

Is a lactose-free acitretin product commercially defensible?

It can provide incremental differentiation, especially in specialty pharmacies, but lactose removal alone is unlikely to create durable market exclusivity.

Can acitretin be delivered in a softgel?

Yes. A softgel can accommodate a lipid or self-emulsifying fill, but shell compatibility, leakage, oxidation, stability, and manufacturing scale-up must be controlled.

Does acitretin have biosimilar competition?

No. Acitretin is a synthetic small molecule. Competition comes from generic products and potential reformulations, not biosimilars.

What patent claim is most valuable for an acitretin reformulation?

A claim linking a defined excipient composition to a clinically demonstrated reduction in food effect is likely more valuable than a broad claim covering acitretin with an unspecified solubilizer.

References

1. U.S. Food and Drug Administration. (2020). Soriatane (acitretin) capsules prescribing information. FDA/DailyMed.

2. National Library of Medicine. (2024). Acitretin capsule product labeling and inactive ingredients. DailyMed.

3. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations. FDA Orange Book.

4. U.S. Food and Drug Administration. (2024). Applications covered by section 505(b)(2). FDA Center for Drug Evaluation and Research.